Additionally, elevated serum IGFBP-2 levels have been detected in systemic sclerosis-associated interstitial lung disease (SSc-ILD), and are associated with deterioration of lung function, while treatment with anti-fibrotic agents pirfenidone and nintedanib reduces serum IGFBP-2 [109]. The gene discussed is IGFBP2; the disease is systemic sclerosis.